MEDSIR

MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients

by

JERSEY CITY, N.J., June 9, 2023 /PRNewswire/ — MEDSIR announced today the results of the PALMIRA trial. This randomized phase 2 study evaluated the safety and efficacy of palbociclib maintenance in combination with second-line endocrine therapy in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer who had showed a confirmed progressive disease on first-linepalbociclib plus … Read more

MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients

by

JERSEY CITY, N.J., June 5, 2023 /PRNewswire/ — MEDSIR announced today the results of the PALMIRA trial. This randomized phase 2 study evaluated the safety and efficacy of palbociclib maintenance in combination with second-line endocrine therapy in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer who had showed a confirmed progressive disease on first-line palbociclib … Read more

MEDSIR’s PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer

by

MEDSIR PHERGain trial is the first to use an adaptive design in HER2-positive early breast cancer.  Tweet this PHERGain is a randomized, controlled phase 2 clinical trial that involved 356 early-stage HER2-positive breast cancer patients from 45 centers in seven European countries. It was sponsored by MEDSIR, a company dedicated to advancing clinical research in … Read more